AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab)...
AbbVie
AbbVie, in fierce fight for eczema market, creates short documentary to show benefits of...
AbbVie's Skyrizi tops the charts for February's leading TV drug ad spenders, as Pfizer's...
Sanofi, Regeneron launch new Dupixent asthma TV ad urging patients to 'Du More' water...
AbbVie and Capsida join forces to focus on serious eye diseases,AbbVie will work with...
